3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
26
Leukemia, Myeloid, Acute
24
Recurrence
12
Sarcoma
7
Lymphoma, Large B-Cell, Diffuse
6
Neoplasm Metastasis
5
Neurofibrosarcoma
4
Neoplasms, Plasma Cell
4
Lymphoma
4
Triple Negative Breast Neoplasms
3
Ovarian Neoplasms
3
Myelodysplastic Syndromes
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Extranodal NK-T-Cell
3
Lymphoma, B-Cell
3
Thymoma
2
Rhabdoid Tumor
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Melanoma
2
Lymphoma, Mantle-Cell
2
Liposarcoma
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Biphenotypic, Acute
2
Leukemia
2
Congenital Abnormalities
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Breast Neoplasms
2
Wilms Tumor
1
Interventions
Dexamethasone
38
Melphalan
20
Bortezomib
18
Cyclophosphamide
17
Calcium Dobesilate
14
Filgrastim
13
daratumumab
11
Peripheral Blood Stem Cell Transplantation
10
pomalidomide
9
Lenalidomide
8
fludarabine phosphate
7
dexamethasone acetate
6
Whole-Body Irradiation
6
Mycophenolic Acid
6
Granulocyte Colony-Stimulating Factor
5
Cyclosporine
5
venetoclax
4
ixazomib
4
dexamethasone 21-phosphate
4
Thalidomide
4
Etoposide
4
Busulfan
4
auricularum
3
Tacrolimus
3
Radiotherapy
3
Focal Adhesion Protein-Tyrosine Kinases
3
Epoetin Alfa
3
Doxycycline
3
Darbepoetin alfa
3
Thiotepa
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Immunoglobulin Light-chain Amyloidosis
×
selinexor
×
Clear all
NCT04984330
2022-11-17
STARR
Weill Medical College of Cornell University
Phase EARLY_PHASE1
Withdrawn